| Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis FX Blanc, T Sok, D Laureillard, L Borand, C Rekacewicz, E Nerrienet, ... New England Journal of Medicine 365 (16), 1471-1481, 2011 | 854 | 2011 |
| Abortion care guideline World Health Organization World Health Organization, 2022 | 269 | 2022 |
| AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d’Ivoire X Anglaret, A Minga, D Gabillard, T Ouassa, E Messou, B Morris, M Traore, ... Clinical infectious diseases 54 (5), 714-723, 2012 | 128 | 2012 |
| Performance of Xpert MTB/RIF and alternative specimen collection methods for the diagnosis of tuberculosis in HIV-infected children O Marcy, V Ung, S Goyet, L Borand, P Msellati, M Tejiokem, ... Clinical infectious diseases 62 (9), 1161-1168, 2016 | 106 | 2016 |
| Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV … FX Blanc, T Sok, D Laureillard, L Borand, C Rekacewicz, E Nerrienet, ... XVIII International AIDS Conference, 18-23, 2010 | 104 | 2010 |
| Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial D Laureillard, O Marcy, Y Madec, S Chea, S Chan, L Borand, ... Aids 27 (16), 2577-2586, 2013 | 87 | 2013 |
| Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis P Pean, E Nerrienet, Y Madec, L Borand, D Laureillard, M Fernandez, ... Blood, The Journal of the American Society of Hematology 119 (14), 3315-3320, 2012 | 75 | 2012 |
| Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial O Marcy, D Laureillard, Y Madec, S Chan, C Mayaud, L Borand, N Prak, ... Clinical infectious diseases 59 (3), 435-445, 2014 | 69 | 2014 |
| Dependence of Efavirenz- and Rifampicin-Isoniazid–Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms … J Bertrand, C Verstuyft, M Chou, L Borand, P Chea, KH Nay, FX Blanc, ... The Journal of infectious diseases 209 (3), 399-408, 2014 | 66 | 2014 |
| Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1–infected adults receiving antiretroviral therapy in Africa and Asia: Data From the ANRS … D Gabillard, C Lewden, I Ndoye, R Moh, O Segeral, B Tonwe-Gold, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 62 (5), 555-561, 2013 | 63 | 2013 |
| Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study K Zürcher, M Ballif, L Fenner, S Borrell, PM Keller, J Gnokoro, O Marcy, ... The Lancet Infectious diseases 19 (3), 298-307, 2019 | 58 | 2019 |
| TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB V Haridas, P Pean, LD Jasenosky, Y Madec, D Laureillard, T Sok, S Sath, ... Aids 29 (3), 263-273, 2015 | 46 | 2015 |
| A treatment-decision score for HIV-infected children with suspected tuberculosis O Marcy, L Borand, V Ung, P Msellati, M Tejiokem, KT Huu, V Do Chau, ... Pediatrics 144 (3), 2019 | 45 | 2019 |
| Prevalence of lung function impairment in cured pulmonary tuberculosis patients in Cotonou, Benin AA Fiogbe, G Agodokpessi, JF Tessier, D Affolabi, DM Zannou, G Ade, ... The International Journal of Tuberculosis and Lung Disease 23 (2), 195-202, 2019 | 36 | 2019 |
| Paediatric tuberculosis–new advances to close persistent gaps BJ Marais, S Verkuijl, M Casenghi, R Triasih, AC Hesseling, ... International Journal of Infectious Diseases 113, S63-S67, 2021 | 35 | 2021 |
| Mortality from drug-resistant tuberculosis in high-burden countries comparing routine drug susceptibility testing with whole-genome sequencing: a multicentre cohort study K Zürcher, ML Reichmuth, M Ballif, C Loiseau, S Borrell, M Reinhard, ... The Lancet Microbe 2 (7), e320-e330, 2021 | 33 | 2021 |
| Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non … N De Castro, O Marcy, C Chazallon, E Messou, S Eholié, JB N'takpe, ... The Lancet Infectious Diseases 21 (6), 813-822, 2021 | 31 | 2021 |
| Low prevalence of drug resistance transmitted virus in HIV Type 1-infected ARV-naive patients in Cambodia J Nouhin, S Ngin, PR Martin, O Marcy, L Kruy, F Ariey, M Peeters, ... AIDS research and human retroviruses 25 (5), 543-545, 2009 | 30 | 2009 |
| Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study O Marcy, M Tejiokem, P Msellati, KT Huu, V Do Chau, DT Ngoc, B Nacro, ... The Lancet HIV 5 (2), e87-e95, 2018 | 28 | 2018 |
| Dyslipidemias and elevated cardiovascular risk on lopinavir-based antiretroviral therapy in Cambodia S Limsreng, O Marcy, S Ly, V Ouk, H Chanroeurn, S Thavary, B Boroath, ... PLoS One 11 (8), e0160306, 2016 | 27 | 2016 |
